Treatment group | N | RDT positve (%) | Ultra sensitive RDT positive (%) | HRP-2 positive (%) | HRP-2 concentration (pg/mL), median (IQR) | p-value | Adjusted p-value | |
---|---|---|---|---|---|---|---|---|
0 | ACT | 50 | 40 (80) | 46 (92) | 46 (92) | > 2800 (2704.3– > 2800) | 0.597 | 0.944 |
ACT + PQ | 50 | 45 (90) | 49 (98) | 47 (94) | > 2800 (> 2800– > 2800) | |||
2 | ACT | 50 | 31 (62) | 44 (88) | 41 (82) | 1469.6 (538.2– > 2800) | 0.375 | 0.679 |
ACT + PQ | 49 | 39 (79.69) | 46 (93.9) | 44 (89.8) | > 2800 (582.2– > 2800) | |||
7 | ACT | 50 | 26 (52) | 42 (84) | 38 (76) | 197.3 (69.3–400.8) | 0.210 | 0.453 |
ACT + PQ | 48 | 30 (62.5) | 44 (91.7) | 35 (72.9) | 393.3 (53.1–2056.2) | |||
14 | ACT | 49 | 15 (30.6) | 29 (59.2) | 21 (42.9) | 40.7 (26.4–1600.6) | 0.552 | 0.957 |
ACT + PQ | 48 | 21 (43.8) | 38 (79.2) | 22 (45.8) | 43.05 (26.3–229.6) | |||
21 | ACT | 44 | 9 (20.5%) | 22 (50) | 9 (20.5) | 32.6 (25.8–46.6) | 0.871 | 0.577 |
ACT + PQ | 46 | 15 (32.69%) | 32 (69.6) | 11 (23.9) | 28.05 (24.8–49.7) | |||
28 | ACT | 45 | 5 (11.1%) | 12 (26.7) | 4 (8.9) | 26.6 (23.9–32.6) | 0.503 | 0.479 |
ACT + PQ | 45 | 9 (20%) | 15 (33.3) | 8 (17.8) | 26.4 (23.9–30.5) | |||
35 | ACT | 45 | 2 (4.4%) | 7 (15.6) | 3 (6.7) | 23.9 (23.7–27.5) | 0.217 | 0.154 |
ACT + PQ | 45 | 5 (11.1%) | 12 (26.7) | 2 (4.4) | 25.3 (23.7–32.6) | |||
42 | ACT | 44 | 0 (0%) | 5 (11.4) | 1 (2.3) | 23.9 (23.7–25.8) | 0.419 | 0.414 |
ACT + PQ | 45 | 0 (0%) | 5 (11.1) | 2 (4.4) | 23.9 (23.7–27.5) | |||
49 | ACT | 44 | 0 (0%) | 2 (4.5) | 0 (0) | 23.9 (23.7–26.4) | 0.253 | 0.365 |
ACT + PQ | 45 | 0 (0%) | 5 (11.1) | 0 (0) | 23.9 (< 6.8–26.4) |